Company news
Aligos Therapeutics, Inc. (NASDAQ:ALGS) news
Aligos Therapeutics, Inc. news releases on 6ix. Latest, Sep 30, 2024: Aligos Therapeutics to Present at Investor Conferences in October
Press releases — page 2
Aligos Therapeutics to Present at Investor Conferences in October
September 29, 2024
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 23, 2024
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
September 18, 2024
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
September 17, 2024
Aligos Therapeutics Announces Reverse Stock Split
August 14, 2024
Aligos Therapeutics Strengthens Board with Two New Independent Directors
August 7, 2024
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
August 5, 2024
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
July 21, 2024
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
July 9, 2024
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 21, 2024
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 20, 2024
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
May 6, 2024
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
April 29, 2024
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 24, 2024
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 2, 2024
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 26, 2024
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
March 17, 2024
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
March 4, 2024
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
February 12, 2024
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
December 6, 2023
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
November 12, 2023
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
November 9, 2023
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
November 1, 2023
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
October 25, 2023
Aligos Therapeutics Announces $92 Million Private Placement Financing
October 22, 2023
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
October 2, 2023
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
September 20, 2023
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
August 2, 2023
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
July 26, 2023
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
July 18, 2023
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 20, 2023
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 6, 2023
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
May 23, 2023
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
May 11, 2023
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
May 3, 2023
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
April 26, 2023
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
April 10, 2023
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
March 28, 2023
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
March 8, 2023
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
February 27, 2023
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
February 7, 2023
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
December 13, 2022
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
November 3, 2022
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
November 1, 2022
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
October 18, 2022
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
October 17, 2022
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
October 13, 2022
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
August 3, 2022
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
July 26, 2022